Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S announced that the European Commission (EC) has approved Abilify Maintena 960 mg (aripiprazole) as a once-every-two-months long-acting injectable (LAI) formulation for the maintenance treatment of schizophrenia in adult patients stabilised with aripiprazole.
29 March 2024-Shareholders of Sosei Group on March 27 approved the company’s proposal to change its corporate name to “Nxera Pharma,” effective April 1. The name Nxera was coined from the words “Next” and “Era” to “express the company’s determination to be a leader in the next era of science and healthcare,”
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. announced that the FDA has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by Akebia.